ProKidney Presents Rilparencel Mechanism-of-Action Findings in Advanced Kidney Disease
Bitget2026/10/27 14:54- ProKidney expects Phase 3 PROACT 1 enrollment to exceed 500 patients, up from 470, with completion targeted for Q1 2027.
- Topline rilparencel eGFR slope results are expected in Q2 2027; the efficacy analysis is expected to include approximately 320 patients.
- A biologics license application submission is targeted for Q1 2028, with accelerated approval and commercial launch anticipated in the first half of 2029.
- Confirmatory endpoint results supporting full approval are expected in the second half of 2029.
- Translational studies suggest rilparencel reduces oxidative damage and inflammatory signaling while supporting vascular integrity under chronic kidney disease-relevant conditions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Orient Precision Industries Holds Extraordinary Shareholders Meeting
Citi optimistic about international oil companies: low-cost resource reserves being rebuilt may drive energy sector to reverse a decade-long valuation discount
With oil prices in the mid-$70s range, Citi believes that global international oil companies (IOCs) can deliver a free cash flow yield of 7% to 8%, and achieve a real growth rate of 4% to 5% over a period of time.
Crypto prices
More
